B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
NCT ID: NCT03332121
Last Updated: 2021-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2018-03-22
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B001,B001 dose escalation
5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
B001
4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
B001
4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with the following histologically-documented hematologic malignancy: CD20 positive B-cell non Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to 2016 WHO Classification of Lymphoma.
3. Patients with relapsed/refractory CD20 positive B cell NHL (including CLL/SLL )
4. Life expectancy of at least 6 months.
5. ECOG-PS score of 0-1.
6. For patients of reproductive potential, pregnancy test should be negative 7 days before treatment , and use of a reliable means of contraception during the study and 12months after discontinuing treatment. Males should be willing to use barrier contraception during the study and 12months after discontinuing treatment.
7. Provision of signed and dated ,written informed consent prior to any study specific procedures, sampling and analyses.
Exclusion Criteria
* Absolute neutrophil count(ANC)\<1.0\*10\^9/L（Except for those with bone marrow invasion）
* Lymphocyte Count(LYM)\>50\*10\^9/L
* Haemoglobin(Hb)\<70g/L（Except for those with bone marrow invasion）
* Platelet count(PLT)\<50\*10\^9/L（Except for those with bone marrow invasion）
* Creatinine (Cr)\>1.5xULN
* Alanine transaminase (ALT)or Aspartate aminotransferase(AST)\>2.5xULN
* Total bilirubin (TBIL)\>2xULN
2. Patients with any anti-tumor treatment (including steroid treatment) within 4 weeks or with any chronic unresolved toxicities from prior therapy greater than Grade 2 according to NCI-CTCAE 4.03.
3. Rituximab or any other anti-CD20 monoclonal antibody treatment within 3 weeks.
4. received blood transfusion and hemopoietic stimulating factor,eg. colony-stimulating factor (CSF)、Erythropoietin(EPO) within 2 weeks.
5. Radiotherapy within 3 months.
6. Major surgery within 28 days
7. History of tumor vaccine treatment.
8. Live-virus (live attenuated) vaccine treatment within 28 days
9. High dose of steroid treatment (hydroprednisone \>10mg/day or relevant dose of other drugs)
10. Patients with history of hematopoietic stem cell transplantation or planning to receive hematopoietic stem cell transplantation within 3 months.
11. Patients with history of Gastrointestinal perforation and/or fistula within 6 months.
12. Lymphoma in CNS, ADIS related lymphoma
13. Active infection by bacteria,virus,fungus which required hospitalization or severe infection required intravenous administration of antibiotics
14. Concomitant severe disease including but not limited to:
* Known HIV or ADIS related disease
* Asthma or interstitial lung disease or severe COPD
* Myocardial infarction, unstable angina, Cardiovascular interventional surgery, Congestive heart failure(CHF; NYHA Grade II-IV), symptomatic or poorly controlled arrhythmia within 6 months before enrolling
* The systolic pressure ≥140mmHg,or diastolic pressure≥90mmHg post treatment.
* Acute or chronic hypotension(\<90/60mmHg)
* History of toxic epidermal necrolysis or Stevens-Johnson syndrome
* Rheumatoid arthritis Granulomatous angiitis or microscopic polyangiitis
* Ileus or history of following disease: inflammatory bowel disease or extensive intestinal resection(extensive bowel resection or hemicolectomy, combining chronic diarrhea), Crohn's disease, ulcerative colitis or chronic diarrhea.
* Previous or concomitant malignant, except basal-cell carcinoma or squamous cell carcinoma and/or cervical carcinoma in situ or effectively treated hematological malignancy and solid tumor that has been remission for more than 3 years and is considered to be cured.
* Any history may affect the study result: increasing dosing risk or affect lab values and Judgment by the investigator that the patient should not participate in the study,
15. HBsAg positive; HBcAb positive and HBV-DNA≥upper limit of detection, HCV positive; HIV positive
16. Allergy to humanized antibody or human-mouse chimeric antibody.
17. Woman who are breast feeding or pregnant
18. Judgment by the investigator that the patient should not participate in the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lugui Qiu, Doctor
Role: PRINCIPAL_INVESTIGATOR
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Junyuan Qi, Doctor
Role: PRINCIPAL_INVESTIGATOR
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The second affiliated hospital of Guangzhou medical university
Guangzhou, Guangdong, China
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B001-101
Identifier Type: -
Identifier Source: org_study_id